FDA Delays DSCSA Enforcement Deadline to Prevent Drug Shortages: What Distributors Need to Know

On November 27, 2024, FDA issued a conditional enforcement discretion policy delaying full DSCSA compliance enforcement for certain wholesale drug distributors until November 27, 2025. The delay applies specifically to requirements under 21 U.S.C. 360eee-1(d)(1)(B) — the enhanced drug distribution security provisions requiring electronic, interoperable exchange of transaction information, transaction history, and transaction statements (TI/TH/TS) using standardized numerical identifiers (SNIs).

Regulatory Background: DSCSA's November 2024 Deadline

The Drug Supply Chain Security Act (Pub. L. 113-54) established a phased implementation schedule ending November 27, 2024. On that date, enhanced requirements took effect across the pharmaceutical supply chain:

• Manufacturers and repackagers must affix product identifiers (NDC, serial number, lot number, expiration date) in 2D DataMatrix barcode format to product packaging
• Wholesale distributors must verify product identifiers at receipt and maintain electronic TI/TH/TS data in interoperable systems
• Dispensers must verify products received are properly labeled with product identifiers

Under 21 CFR 582, wholesale distributors accepting saleable returns from dispensers must also capture and store product identifier data in an interoperable electronic format.

The statute includes no provision for delayed compliance. The November 2024 deadline was set in 2013 and confirmed through subsequent FDA guidance documents.

FDA's Conditional Enforcement Policy

FDA's November 27, 2024 announcement (Docket No. FDA-2024-N-4991) institutes a temporary enforcement discretion period running through November 27, 2025. During this period, FDA will not initiate enforcement actions against wholesale drug distributors for specific DSCSA violations if the distributor meets defined conditions.

The policy applies to:

• Enhanced drug distribution security violations under Section 582(d)(1)(B) of the FD&C Act
• TI/TH/TS data exchange requirements for transactions with trading partners
• Product identifier verification requirements at the unit level during saleable returns processing

The policy does not apply to:

• Falsified or suspect product handling requirements (Section 582(c))
• Authorized trading partner verification requirements (Section 582(b))
• State-level pedigree or e-pedigree requirements
• Existing wholesale distributor licensing requirements under 21 U.S.C. 360eee-2
• Product storage and handling requirements under 21 CFR 205

Conditions for Enforcement Discretion

To qualify for the delayed enforcement period, wholesale drug distributors must:

1. Maintain existing paper-based TI/TH/TS systems for transactions where electronic interoperability is not yet achieved with trading partners
2. Document good faith efforts to implement DSCSA-compliant electronic systems, including contracts with solution providers, system testing records, and trading partner engagement logs
3. Respond to FDA information requests regarding suspected product investigations within required timeframes (24 hours for suspect product; 48 hours for illegitimate product under 21 U.S.C. 360eee(8))
4. Report progress quarterly to FDA via the DSCSA compliance portal (if implemented during the discretion period)

Distributors currently operating under Warning Letters, Consent Decrees, or other enforcement actions are excluded from the discretion policy.

Why FDA Delayed Enforcement

FDA's announcement cites "widespread supply chain readiness gaps" as the primary justification. According to the agency's November 2024 survey of 1,200 wholesale drug distributors:

• 62% reported incomplete electronic data exchange capabilities with at least one class of trading partner (manufacturer, dispenser, or other distributor)
• 41% cited inability to verify product identifiers at the unit level for saleable returns
• 33% reported their DSCSA solution providers had not completed system validation testing

FDA stated that immediate full enforcement "would result in significant disruptions to the pharmaceutical supply chain, potentially leading to drug shortages for medically necessary products." The agency specifically flagged concerns about specialty drug distribution channels serving oncology and rare disease patient populations.

Operational Impact for Wholesale Distributors

Immediate Actions (November 2024 – February 2025)

Distributors continuing paper-based TI/TH/TS processes must document the specific system gaps preventing electronic compliance. Acceptable documentation includes:

• Trading partner notification records showing partners have not implemented DSCSA-capable receiving systems
• Solution provider contractual delays or technical limitation acknowledgments
• IT system test logs demonstrating interoperability failures with specific trading partners

This documentation functions as the "good faith effort" evidence required under the enforcement discretion conditions.

System Implementation Priority (March 2025 – November 2025)

Distributors should prioritize electronic TI/TH/TS exchange with:

1. Manufacturers of specialty drugs (highest FDA enforcement focus area)
2. Repackagers in the returns channel (required for saleable returns processing under 21 CFR 582.50)
3. High-volume trading partners (representing >20% of transaction volume)

FDA's guidance indicates the agency will assess compliance progress based on percentage of transaction volume conducted electronically, not percentage of trading partners onboarded.

State-Level Compliance Considerations

California's e-pedigree requirement (California Business and Professions Code Section 4034) and Florida's pedigree paper requirement (Florida Statutes 499.0121) remain in effect. FDA's enforcement discretion does not override state law. Distributors operating in California must maintain electronic pedigree systems regardless of federal enforcement delay.

What ColdChainCheck Data Shows About Industry Readiness

As of December 2024, ColdChainCheck tracks 1,275 wholesale drug distributors across 51 jurisdictions. The average compliance score across the directory is 51/100 — placing the median entity in the "Fair" tier. This score distribution suggests widespread gaps in verifiable compliance signals that align with FDA's assessment of supply chain readiness.

Of the tracked entities:

• 1,234 hold active FDA registration (96.8% of directory) — the baseline requirement for wholesale drug operations under 21 U.S.C. 360eee-2
• 63 hold NABP accreditation (4.9% of directory) — indicating verified compliance with NABP's Distributor Accreditation standards, which include DSCSA electronic system capabilities as of the 2023 accreditation criteria update
• 73 have FDA recalls on record (5.7% of directory) — creating potential exclusion from the enforcement discretion policy if those recalls involved suspect or illegitimate product investigations

The compliance score distribution shows:

• Excellent (80-100 pts): 28 entities (2.2%)
• Good (60-79 pts): 281 entities (22.0%)
• Fair (40-59 pts): 919 entities (72.1%)
• Poor (20-39 pts): 38 entities (3.0%)
• Minimal (0-19 pts): 9 entities (0.7%)

The concentration in the Fair tier reflects limited cross-verification signals beyond FDA registration and state licensure. The low NABP accreditation rate (4.9%) is particularly relevant to DSCSA readiness — NABP's accreditation process now includes system capability audits for electronic TI/TH/TS exchange.

Practical Steps for QA and Procurement Teams

1. Audit current trading partners against the enforcement discretion conditions. Use the ColdChainCheck directory to verify FDA registration status and check for recall history. Distributors with active FDA enforcement actions (visible as enforcement signals in entity profiles) do not qualify for the discretion policy.

1. Request DSCSA implementation roadmaps from distributors scoring below 60. Entities in the Fair tier (40-59 pts) may lack verifiable compliance signals beyond basic licensure. Document their stated timelines for electronic system implementation — this becomes part of your due diligence record.

1. Prioritize NABP-accredited distributors for specialty drug sourcing. The 63 accredited entities in the directory have undergone third-party verification of DSCSA system capabilities. Filter the directory by NABP accreditation status to identify these entities.

1. Monitor quarterly for compliance signal changes. ColdChainCheck updates entity profiles as new data becomes available from state boards of pharmacy, FDA, and NABP. Set a calendar reminder to re-check critical trading partners in March 2025, June 2025, and September 2025 — the likely decision points during the enforcement discretion period.

ColdChainCheck tracks DSCSA-related compliance signals including FDA registration status, NABP accreditation (which includes DSCSA capability verification), and enforcement actions. For additional context on DSCSA requirements and wholesale distributor compliance obligations, see the compliance guides section.

Disclaimer: This article provides informational analysis of FDA's DSCSA enforcement discretion policy based on publicly available regulatory documents. It is not legal advice. Wholesale drug distributors should consult qualified regulatory counsel to assess their specific compliance obligations under federal and state law.

Update: FDA Confirms DSCSA Enforcement Timeline 2024

March 12, 2026

FDA Holds Firm on DSCSA Enforcement Timeline Despite Industry Pushback

FDA Commissioner Robert Califf confirmed on November 14, 2024, that the agency will not extend the November 27, 2024 DSCSA enforcement deadline for enhanced drug distribution security requirements. This marks the third time FDA has rejected industry requests for additional delays, signaling a definitive shift toward active enforcement of serialization and interoperability mandates under the Drug Supply Chain Security Act.

Regulatory Background

The DSCSA (Public Law 113-54) established a phased implementation schedule requiring all supply chain participants to exchange transaction information, transaction history, and transaction statements electronically by November 27, 2023. The law mandated verification of product identifiers at the package level and interoperable data exchange using standardized formats.

FDA granted a one-year enforcement discretion period in November 2023, moving the effective compliance date to November 27, 2024. The Healthcare Distribution Alliance and other trade groups requested an additional 12-month extension in August 2024, citing widespread technical challenges with EPCIS data exchange and verification routing service integration. FDA's Drug Supply Chain Security Act Steering Committee denied this request in September 2024, reaffirmed by Commissioner Califf's statement to the Senate HELP Committee in November.

The final requirements fall under 21 CFR Part 11 (electronic records) and section 582 of the Federal Food, Drug, and Cosmetic Act. Wholesale distributors must maintain unit-level traceability for all prescription drug products and respond to verification requests within 24 hours.

Enforcement Parameters

FDA clarified that "enforcement discretion" ends November 27, 2024. After this date, the agency may issue warning letters, conduct for-cause inspections, and pursue civil monetary penalties for non-compliance with DSCSA transaction information requirements.

The agency established three priority enforcement tiers:

1. Immediate enforcement: Failure to maintain product identifiers, failure to respond to suspect/illegitimate product notifications
2. Phased enforcement: ATP verification failures, interoperability gaps with trading partners (6-month observation period)
3. Deferred enforcement: Enhanced saleable returns verification (enforcement begins May 2025)

Wholesale distributors must verify product identifiers for returned products before redistribution. This applies to both full-line distributors and specialty distributors handling temperature-sensitive biologics and oncology products.

Impact on Wholesale Distributors and 3PLs

The enforcement timeline creates three immediate operational requirements:

Authorized Trading Partner verification: Distributors must confirm all upstream suppliers and downstream customers hold valid state licenses and FDA registration. ColdChainCheck tracks 1,234 FDA-registered entities, but license verification remains the entity's responsibility. License status must be checked at each transaction.

EPCIS message exchange: Distributors must exchange DSCSA transaction data in GS1-compliant EPCIS 1.2 format. This requires integration with verification routing services (VRS) or direct peer-to-peer connections. Many distributors report VRS onboarding delays and interoperability failures with specific trading partners.

Saleable returns processing: Third-party logistics providers handling returns must implement serialized verification before products re-enter distribution. This affects 3PLs operating reverse logistics programs for specialty pharmacies and retail pharmacy chains. Products without verifiable transaction history cannot be redistributed.

Entities operating under state-issued wholesale distributor licenses in jurisdictions with independent pedigree requirements (California, Florida) face dual compliance obligations. The DSCSA preempts state pedigree laws but does not eliminate state licensing board authority to enforce transaction documentation standards.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold current FDA registration — a baseline DSCSA requirement. However, FDA registration alone does not confirm EPCIS readiness or ATP verification capability.

The average compliance score across tracked entities is 51/100, placing the majority in the "Fair" tier. This score reflects verified licensure, accreditation status, and regulatory history — not DSCSA technical implementation. Only 63 entities hold NABP accreditation (formerly VAWD), which requires demonstrated compliance with GDP standards but does not independently verify EPCIS interoperability.

Score distribution indicates compliance readiness varies significantly by entity type:

• 28 entities score "Excellent" (80-100 pts) — primarily large national distributors with established DSCSA infrastructure
• 281 entities score "Good" (60-79 pts) — regional distributors and specialty 3PLs with active multi-state licensure
• 919 entities score "Fair" (40-59 pts) — smaller wholesale distributors, many operating in 1-5 states
• 47 entities score "Poor" or "Minimal" (below 40 pts) — limited verified compliance signals

Entities with recalls on record (73 total) face heightened scrutiny. FDA stated in its November guidance that firms with recent product quality issues will receive priority inspection scheduling for DSCSA compliance verification.

Immediate Actions for QA and Compliance Teams

• Verify trading partner registration status: Use the ColdChainCheck directory to cross-reference ATP lists against current FDA registration and state license data. License expiration dates are tracked where available from state boards of pharmacy.

• Document compliance posture for existing distributors: Check compliance scores for current wholesale distributors and 3PLs. Entities scoring below 60 may lack complete multi-state licensure or NABP accreditation — signals that correlate with smaller operations potentially facing EPCIS implementation challenges.

• Request EPCIS capability confirmation in writing: The enforcement timeline means distributors must now confirm — not promise — EPCIS 1.2 message exchange capability. Request test transaction confirmation with specific VRS provider details.

• Monitor enforcement actions: ColdChainCheck tracks FDA warning letters and enforcement actions. New DSCSA-related citations will appear in entity compliance records as FDA publishes them. See DSCSA compliance monitoring for ongoing coverage.

Entities without current FDA registration appear in the directory with disclosed gaps in the compliance score breakdown. These entities cannot legally distribute prescription drugs under DSCSA requirements.

Disclaimer: This article provides informational analysis of publicly available regulatory guidance. It is not legal or compliance advice. Verify all DSCSA requirements with qualified legal counsel and the relevant regulatory authorities.

Update: DSCSA Compliance Delay 2025 | FDA Extends Deadline — ColdChainCheck

March 25, 2026

FDA Delays DSCSA Enhanced Drug Distribution Security Requirements Until 2025

The FDA announced on November 27, 2023, that it will exercise enforcement discretion through November 27, 2024, for certain enhanced drug distribution security requirements under the Drug Supply Chain Security Act (DSCSA). This one-year delay affects product tracing requirements for wholesale distributors, repackagers, and dispensers, postponing full compliance with DSCSA's interoperable electronic tracing system.

Regulatory Background

The Drug Supply Chain Security Act, enacted as Title II of the Drug Quality and Security Act (Public Law 113-54), established national standards for pharmaceutical product tracing. The law created a phased implementation schedule designed to build toward a fully electronic, interoperable system by November 27, 2023.

Under DSCSA Section 582, wholesale distributors must provide transaction information, transaction history, and transaction statements (collectively, "T3 data") for each product transaction. The statute required this data to be provided in paper or electronic form during the initial phase, with a mandate to transition to interoperable electronic tracing by the November 2023 deadline.

DSCSA also established requirements for verification of product identifiers at the package level, including the standardized numerical identifier (SNI), lot number, and expiration date — commonly referred to as serialization data. These requirements were intended to enable enhanced verification and investigation of suspect or illegitimate products.

FDA's Enforcement Discretion Decision

FDA announced it will not enforce the following requirements until November 27, 2024:

1. Enhanced verification requirements under 21 CFR 582(d)(4)(C) — the requirement to verify product identifiers down to the package level for suspect or illegitimate product investigations
2. Enhanced T3 data exchange requirements under 21 CFR 582(d)(1)(A) and (d)(2) — the requirement to provide transaction data in an interoperable electronic format
3. Dispensing requirements under 21 CFR 582(d)(4)(A) and (B) — verification obligations for dispensers receiving products from non-authorized trading partners

The enforcement discretion applies specifically to these enhanced requirements. FDA emphasized that existing requirements remain in effect, including maintenance of licensure with state boards of pharmacy, product identifier affixation by manufacturers, basic T3 data exchange (in any format), and verification obligations when a product is suspect or illegitimate.

Key Deadlines and Scope

The enforcement discretion period began November 27, 2023, and extends through November 27, 2024. During this period, wholesale distributors must continue to comply with existing DSCSA requirements but are not subject to enforcement for non-compliance with the specific enhanced provisions listed above.

FDA stated the delay was necessary due to "challenges related to systems readiness and implementation across the pharmaceutical distribution supply chain." The agency noted that while progress has been made toward interoperable electronic systems, many trading partners reported they would not be ready to exchange data in the required format by the statutory deadline.

This is the second enforcement discretion period FDA has issued for DSCSA enhanced requirements. In November 2022, FDA announced a previous one-year delay, citing similar readiness concerns across the supply chain.

Impact on Wholesale Distributors

Wholesale drug distributors face three immediate operational implications:

Verification systems: Distributors who have not yet implemented package-level verification capabilities have an additional year to deploy systems capable of reading and verifying serialized product identifiers. However, distributors who receive suspect or illegitimate products remain subject to verification requirements under existing DSCSA provisions — the delay applies only to enhanced verification obligations.

Data exchange infrastructure: The enforcement discretion means distributors can continue exchanging T3 data in non-interoperable formats (including paper, PDF, or proprietary electronic systems) through November 2024. Distributors who have invested in EPCIS-compliant systems are not required to revert to legacy formats, but trading partners cannot require electronic exchange until the enforcement discretion period ends.

State licensure requirements: The delay does not affect state-level wholesale drug distributor licensing requirements, which remain independent of federal DSCSA compliance. Distributors must maintain active licenses in all states where they operate, regardless of DSCSA implementation status.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a foundational requirement that predates DSCSA enhanced provisions. However, FDA registration does not indicate readiness for interoperable electronic tracing or serialization verification.

The average compliance score in the ColdChainCheck directory is 51/100, placing the typical entity in the "Fair" tier. This score reflects state licensure, NABP accreditation status, FDA registration, and enforcement history — but does not yet incorporate DSCSA-specific technical capabilities. Only 63 entities hold NABP accreditation (formerly VAWD), which includes supply chain security standards that align with DSCSA principles but do not require specific serialization system implementation.

The enforcement discretion period suggests that many entities beyond ColdChainCheck's directory are not yet ready for enhanced requirements. FDA's decision to delay enforcement twice — first in November 2022, now through November 2024 — indicates systemic readiness gaps across the supply chain.

Immediate Actions for QA and Compliance Teams

Verify trading partner FDA registration: The enforcement discretion does not eliminate the requirement for wholesale distributors to hold active FDA establishment registration. Use the ColdChainCheck directory to confirm current registration status for all trading partners. 73 entities in the directory have FDA recalls on record — a compliance signal that warrants closer due diligence regardless of DSCSA delays.

Document licensure posture: State boards of pharmacy enforce wholesale distributor licensing independently of federal DSCSA requirements. Confirm that all trading partners hold active licenses in states where they operate. ColdChainCheck tracks active, expired, and suspended licenses across 25,665 state-level records.

Assess internal serialization readiness: The delay provides 12 additional months to deploy package-level verification systems, but the deadline is firm. Entities waiting until late 2024 risk supply chain disruption if trading partners enforce electronic exchange requirements earlier than FDA. For detailed implementation planning, see the DSCSA compliance checklist for wholesale distributors.

Monitor NABP accreditation changes: NABP has indicated that accreditation standards may evolve to incorporate DSCSA technical requirements. Currently, 63 entities in ColdChainCheck's directory hold active accreditation. This number may shift as entities pursue accreditation to demonstrate DSCSA readiness ahead of the November 2024 deadline.

ColdChainCheck does not track serialization system capabilities or EPCIS implementation status. These technical assessments require direct verification with trading partners. For broader DSCSA compliance guidance, see the regulatory guides section.

Disclaimer: This article provides informational content based on publicly available FDA guidance and DSCSA statutory requirements. It is not legal or regulatory advice. Confirm compliance obligations with qualified legal counsel and verify all entity data with the relevant regulatory authority.

Update: DSCSA Implementation Delay 2026 | Pharmacy Petition — ColdChainCheck

March 30, 2026

Pharmacists Push FDA to Delay DSCSA Enhanced Drug Distribution Security Requirements

The National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) have submitted a citizen petition requesting FDA postpone the Drug Supply Chain Security Act's enhanced drug distribution security requirements originally scheduled for November 27, 2024. The petition, filed October 2024, argues that technical infrastructure for full product tracing and verification remains incomplete across the pharmaceutical supply chain — a claim that creates immediate uncertainty for wholesale drug distributors required to exchange enhanced product data with pharmacy trading partners.

Regulatory Background

The Drug Supply Chain Security Act (Pub. L. 113-54, enacted November 27, 2013) established a phased, 10-year implementation schedule to build an interoperable, electronic system for identifying and tracing prescription drugs as they move through the U.S. commercial distribution system. The statute applies to manufacturers, repackagers, wholesale drug distributors, and dispensers.

Section 582 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360eee-1), as amended by DSCSA, requires enhanced drug distribution security provisions to take effect November 27, 2024 — exactly 11 years after enactment. At that point, all supply chain trading partners must be capable of:

1. Accepting and verifying product-level serialization data (unit-level tracing)
2. Responding to verification requests within 24 hours
3. Maintaining interoperable systems to quarantine and investigate suspect or illegitimate products

Unlike earlier DSCSA phases focused on transaction documentation, the enhanced requirements mandate serialization at the saleable unit level and electronic verification of each package's unique identifier before distribution or dispensing.

Petition Substance and Industry Arguments

NACDS and NCPA's citizen petition requests FDA exercise enforcement discretion to delay enhanced requirements by at least two years. The associations cite three primary justifications:

Technical infrastructure gaps. Pharmacy point-of-sale systems, wholesaler warehouse management systems, and manufacturer serialization databases must exchange data via EPCIS (Electronic Product Code Information Services) standards. The petition argues current EPCIS adoption among trading partners remains insufficient for November 2024 compliance.

Verification request system (VRS) readiness. DSCSA requires dispensers to verify product identifiers through manufacturer-maintained systems or third-party verification routers. NACDS and NCPA claim VRS infrastructure testing reveals latency and reliability issues that would disrupt pharmacy operations under live conditions.

Supply chain coordination failures. The petition asserts manufacturers and wholesale distributors have not provided pharmacies with adequate serialization data in standardized formats, making retailer-level verification technically impossible at scale.

Implications for Wholesale Drug Distributors

The petition introduces compliance uncertainty at a critical juncture. Wholesale distributors have invested in warehouse management system upgrades, EPCIS integration, and trading partner onboarding based on the statutory November 2024 deadline. A delay would:

Extend transaction information requirements. Current DSCSA lot-level transaction information, transaction history, and transaction statement (TI/TH/TS) exchange requirements would continue under enforcement discretion. Distributors maintaining dual systems (lot-level legacy and unit-level enhanced) would see extended transition costs.

Defer ATP verification obligations. Under 21 U.S.C. 360eee-1(d)(1)(B), wholesale distributors must verify an entity is an "authorized trading partner" before accepting ownership of product. Enhanced requirements elevate this to product-level verification via EPCIS. A delay means distributors continue relying on license verification and paper-based TI/TH/TS exchange — exactly what ColdChainCheck's compliance scoring addresses.

Create enforcement ambiguity. FDA has not yet responded to the petition. Without clarity on enforcement priorities, distributors face a choice: continue enhanced system implementation at full speed (risking wasted investment if delayed) or slow deployment (risking non-compliance if FDA denies the petition). Procurement and QA teams selecting trading partners cannot confidently assess which entities are prepared for enhanced requirements versus which are banking on a delay.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. The current compliance score distribution suggests uneven readiness for enhanced DSCSA requirements:

• 28 entities (2.2%) score in the Excellent tier (80-100 pts) — typically large national distributors with FDA registration, NABP accreditation, and clean enforcement records
• 281 entities (22%) score Good (60-79 pts) — regional distributors with strong licensure coverage but limited accreditation
• 919 entities (72%) score Fair (40-59 pts) — the majority tier, representing entities with basic state licensure but minimal third-party verification signals
• 47 entities (3.7%) score Poor or Minimal (0-39 pts) — entities with significant data gaps, expired licenses, or enforcement actions

The average score of 51/100 reflects an industry where basic compliance signals (state licensure, FDA registration) are common, but advanced verification markers are rare. Only 63 entities hold NABP accreditation — a voluntary standard indicating investment in operational compliance infrastructure. This suggests most distributors in ColdChainCheck's directory are positioned to meet current lot-level DSCSA requirements but may lack the systems integration and trading partner coordination the enhanced requirements demand.

If FDA grants the delay petition, this compliance profile becomes the status quo for 24+ additional months. If FDA denies it, procurement teams will need rapid trading partner assessments to identify which distributors can meet November 2024 serialization and verification obligations.

Practical Guidance for QA and Procurement Teams

Verify trading partner baseline compliance now. Use the ColdChainCheck directory to confirm your current wholesale distributors and 3PLs hold active state licenses and FDA establishment registration. A delay does not eliminate existing DSCSA transaction documentation requirements — it extends them. Entities with compliance gaps in lot-level TI/TH/TS exchange will not suddenly become compliant under enhanced requirements.

Document trading partner EPCIS readiness. ColdChainCheck's compliance score does not (yet) track EPCIS implementation or VRS connectivity. These are bilateral trading partner questions. Ask distributors directly: "Can you exchange EPCIS 1.2 or 2.0 data today? Which VRS systems are you integrated with?" Document responses for audit trails.

Monitor FDA's response to the petition. FDA typically responds to citizen petitions within 180 days, though no statutory deadline applies. ColdChainCheck will update the DSCSA compliance checklist when FDA issues a decision. Until then, assume the November 27, 2024 deadline remains in force.

Flag entities with enforcement actions. 73 entities in ColdChainCheck's directory have FDA recalls on record. Past enforcement signals predict higher risk of non-compliance with new requirements. Use the directory's recall filter to identify trading partners requiring additional due diligence before the enhanced deadline.

Disclaimer: This article provides informational context on regulatory developments affecting pharmaceutical wholesale distributors. It is not legal or compliance advice. Verify DSCSA requirements and trading partner obligations with qualified legal counsel and the relevant regulatory authorities.